(Image via AbbVie)

AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics

Originally posted on Abbvie.com

AbbVie, a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology, and fibrosis.

“Based on our strong switchable CAR-T alliance launched in 2018, we feel the expanded relationship with AbbVie represents a robust path forward for some of our programs, complementing a diverse ecosystem of innovation we’ve created over the past several years at Scripps to advance life-changing therapies,” says Peter Schultz, Ph.D., chief executive officer, Scripps Research and Calibr, its drug discovery division.

In addition to programs initially named in the collaboration from preclinical to IND stages of development, Scripps Research will present to AbbVie a certain number of preclinical programs of mutual interest per year for consideration to be included in the collaboration. Scripps and AbbVie will also work together in parallel to advance CD3 bispecifics against oncology targets nominated by AbbVie.

Under the terms of the license agreement, Scripps Research will continue to conduct pre-clinical research and development activities and, in some cases, Phase 1 clinical trials with AbbVie having an exclusive option to further develop and commercialize.

Upon AbbVie’s decision to exercise its option to a given program, Scripps Research is eligible to receive additional payments from AbbVie, including option exercise fees, success-based development and commercial milestone payments, as well as tiered royalties. AbbVie will make an undisclosed upfront payment, as well as a near-term milestone payment upon achievement of certain success criteria.

“The best way to develop transformational medicines is through collaborations that bring together the brightest minds,” says Mohit Trikha, Ph.D., vice president and head of oncology early development, AbbVie. “This partnership with Scripps Research will collaboratively advance next-generation programs, build stronger relationships with proven and emerging scientific leaders, and most importantly help us advance novel medicines for patients. We are eager to partner with Scripps on these assets as they enter the clinic over the next few years as Scripps has one of the strongest track records of any academic institution when it comes to advancing novel medicines for patients.”

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, FacebookLinkedIn or Instagram.

Latest News

anitab.org, adp, women, grace hopper

ADP Recognized for “World’s Most Admired Companies” List for 14th Consecutive Year

Originally posted on ADP.com ADP Recognized on FORTUNE Magazine’s 2020 “World’s Most Admired Companies” List for 14th Consecutive Year ADP, a leading global technology company providing human capital management (HCM) solutions, has been named by FORTUNE® magazine as one of the “World’s Most Admired Companies” in 2020.  This marks the 14th…

Cigna

Despite Drops in Insurance Coverage in the US, Companies Are Stepping Up

In 2018, 27.5 million people (8.5% of the U.S. population) did not have health insurance. That’s the highest number of uninsured Americans since 2009, according to a report from the US Census Bureau. Despite a strong economy, increasingly more Americans have no coverage. The dip is driven mostly by fewer people qualifying for Medicaid. People of color are particularly affected…

AIG Lynn Oldfield Named CEO of the Year

Lynn Oldfield Named CEO of the Year at Insurance Business Canada Awards  Lynn Oldfield, President and CEO of AIG Canada, was recently named CEO of the year at the Insurance Business Canada awards, in recognition of her “exceptional leadership” and other criteria in excellence. “This award is a reflection of…

EY Crosses Milestone to Help Clients Deploy SAP on Microsoft Azure with Strategy and Solution Initiatives

Originally posted on EY.com EY framework addresses customers’ enterprise technology and strategy for long-term value from transformation EY digital delivery platform offers up to 70% savings in migration More large enterprises seek to accelerate innovation and increase agility across their business by migrating their mission-critical SAP-based processes to the cloud….